ATLANTA, July 26, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that, after a review of safety, tolerability and pharmacokinetic data from the Company's Phase 1 clinical trial of IkT-148009 in healthy volunteers, the United States Food and Drug Administration (FDA) has given the Company clearance to begin a Phase 1b extension study to evaluate its lead drug candidate IkT-148009 in Parkinson's patients.
- Following the review, the Agency met with the Company on July 22, 2021, and granted the company permission to begin evaluation of IkT-148009 in Parkinson's patients.
- "The extension of our Phase 1 study of IkT-148009 for the treatment of Parkinson's disease into patients is an important milestone for Inhibikase.
- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.
- Inhibikase is currently evaluating the safety, tolerability and pharmacokinetics of IkT-148009in older and healthy subjects and Parkinson's patients.